Yayın:
Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment

Sadeleştirilmiş öğe sayfası
dc.contributor.authorOSMANİYE, DERYA
dc.contributor.authorKARADUMAN, ABDULLAH BURAK
dc.contributor.authorÖzkay, Yusuf
dc.contributor.authorYusuf Özkay
dc.contributor.orcid0000-0002-7305-7177
dc.contributor.orcid0000-0002-0499-436X
dc.contributor.orcid0000-0002-0434-1334
dc.contributor.orcid0000-0001-8815-153X
dc.date.accessioned2025-11-13T16:42:09Z
dc.date.issued2025-10-01
dc.identifier.doihttps://doi.org/10.1002/ardp.70122
dc.identifier.endpagee70122
dc.identifier.issn0365-6233
dc.identifier.issue10
dc.identifier.openalexW4415130889
dc.identifier.startpagee70122
dc.identifier.urihttps://hdl.handle.net/11421/10479
dc.identifier.urihttps://doi.org/10.1002/ardp.70122
dc.identifier.volume358
dc.language.isoen
dc.relation.ispartofArchiv der Pharmazie
dc.rightsrestrictedAccess
dc.titleInnovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5017640266
local.authorid.openalexA5030295748
local.authorid.openalexA5030511747

Dosyalar

Koleksiyonlar

Publications